botox competitor
messag revanc announc partnership develop
commerci biosimilar botox agreement provid million up-front
payment revanc like long-term opportun compani plan
provid updat phase cervic dystonia studi phase plantar fasciiti
program analyst day april maintain neutral rate
partnership announc world-wide exclud japan licens
collabor agreement develop commerci biosimilar botox
onabotulinumtoxina agreement receiv up-front payment
elig receiv aggreg payment upon achiev
specifi clinic regulatori mileston tier sale mileston
signific royalti rate sale form joint steer
committe determin specif plan action though expect approv
biosimilar approv glabellar line cervic dystonia
plan discuss strateg plan analyst day april
result report opex vs estim adj ep
versu our/street estim opex quarter higher
expect due non-cash impair relat plant asset
end quarter cash manag expect fund oper
potenti catalyst manag expect initi singl pivot phase trial
cervic dystonia read long-term safeti studi glabellar line
initi second phase trial plantar fasciiti respect cervic
dystonia plan singl global studi fda file compani
still talk ema submiss packag respect plantar fasciiti
plan review full dataset week endpoint vs week interim data report
provid detail modifi design analyst day april
model chang compani reiter guidanc cash burn rang
oper expens rang expens
rang stock-bas compens rang
chang estim time maintain neutral rate hold
analyst day nyc
aad highlight attend american academi dermatolog meet san
diego ca spoke one well-known expert field thought
still mani therapeut indic botulinum toxin kol thought
compound sticki molecul could act potenti piggyback carrier
molecul interestingli pruritu forum present discuss data show agn
posit data botox pruritu howev compani interest pursu
indic perceiv difficulti medic dermatolog field rather
agn want focu cosmet indic
page analyst certif import disclosur
valu revanc use dcf methodolog calcul anticip profit revanc
botulinum toxin product revanc seek approv
glabellar line phase report cervic dystonia phase follow-on plantar
fasciiti studi pend phase failur use discount rate
exit ebitda multipl estim termin year ebitda close
million believ share fairli valu discount rate believ
adequ reflect clinic develop risk yet remain well
regulatori risk execut risk commerci
risk revanc includ clinic develop risk inabl
compani gain approv fda fail clinic studi clinic studi
result addit clinic trial longer expect approv timelin higher
expect cost failur success introduc either market
failur penetr neuromodul market inabl gain formulari accept
receiv unfavor payor reimburs failur develop commerci organ
capabl manufactur sell market distribut product compani
intend sell market choos commerci
perform third parti cmo forecast error determin revanc
market opportun due compani lack yet establish track record
profit limit intellectu properti ip protect control trade secret
technolog innov abil competitor independ develop similar better
proprietari inform techniqu disclos publicli success compet
therapi product becom avail medicar medicaid insur
increas effort manag drug spend econom weak impact unemploy
commerci insur coverag util risk includ compani may
requir substanti addit fund may financ futur cash need primarili
public privat offer debt financ strateg collabor may dilut
stockhold compani
convers could penetr botulinum toxin market expect versu
forecast result upsid estim addit revanc could enter
therapeut market acquir addit asset account
could yield upsid estim
page analyst certif import disclosur
servic
total servic
revenu
revenu
litigation-rel
acquisition-rel charg
purchas in-process
depreci amort
sale/merg expens
interest dividend incom
chang fair valu deriv liabil associ medici settlement
sale asset
realiz gain loss invest
unreal gain loss invest
unreal gain avail sale secur
total servic
compani report guggenheim secur llc estim
page analyst certif import disclosur
